977 related articles for article (PubMed ID: 32178765)
1. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
[TBL] [Abstract][Full Text] [Related]
6. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Coates LC; Gossec L; Theander E; Bergmans P; Neuhold M; Karyekar CS; Shawi M; Noël W; Schett G; McInnes IB
Ann Rheum Dis; 2022 Mar; 81(3):359-369. PubMed ID: 34819273
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
[TBL] [Abstract][Full Text] [Related]
12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
[TBL] [Abstract][Full Text] [Related]
15. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
18. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Schiopu E; Chakravarty SD; Kollmeier AP; Xu XL; Shawi M; Jiang Y; Sheng S; Wang Y; Xu S; Merola JF; McInnes IB; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296534
[TBL] [Abstract][Full Text] [Related]
19. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
